A Physician's Guide to AL (Light Chain) Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Reference Materials

A Physician’s Guide to AL (Light Chain) Amyloidosis

key information

source: Amyloidosis Foundation

year: 2016

authors: Ravi Mareedu, Raymond Q. Migrino

summary/abstract:

Amyloidosis is a disorder in which misfolded native proteins deposit extracellularly and lead to organ damage. Although the various types of amyloidoses share in common the deposition of misfolded proteins that aggregate as fibrils in tissue, they differ in actual protein composition, organ involvement, prognostic implication and most importantly, treatment. It is therefore critically important to determine the type of amyloidosis a patient has in order to provide the appropriate treatment.
 
There are at least 23 different proteins associated with amyloidosis. The most common type of amyloidosis and the one that is associated with a poor prognosis if left untreated is called AL amyloidosis and due to the deposition of clonal immunoglobulin light chains produced by plasma cells in the bone marrow.
 

There are several types of hereditary amyloidoses, most common of which is mATTR amyloidosis, an autosomal dominant disease that results from misfolding of mutant transthyretin, a protein produced in the liver containing a single point gene mutation. More than 100 different transthyretin mutations are known to cause amyloidosis.

 

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close